DGAP-Adhoc: Dermapharm Holding SE: Acquisition of Allergopharma
- 217
|
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Takeover Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU) Dermapharm Holding SE: Acquisition of Allergopharma Grünwald, February 19, 2020 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) signed a contract via Dermapharm Beteiligungs GmbH to acquire Allergopharma GmbH & Co. KG, based in Reinbek near Hamburg, Germany, a subsidiary of Merck KGaA, Darmstadt, Germany. With the closing of the transaction, Dermapharm Beteiligungs GmbH will acquire 100.00 percent of the shares in the company that specializes in desensitization of allergies. The parties have agreed not to disclose the purchase price. The purchase agreement is still subject to the approval of the relevant supervisory authority. The Management Board expects the transaction to be completed by the end of the second quarter of 2020. >End of the Ad hoc announcement<
Contacts
19-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Dermapharm Holding SE |
| Lil-Dagover-Ring 7 | |
| 82031 Grünwald | |
| Germany | |
| Phone: | +49 (0)89 64 86-0 |
| E-mail: | [email protected] |
| Internet: | ir.dermapharm.de |
| ISIN: | DE000A2GS5D8 |
| WKN: | A2GS5D |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: | 979211 |
| End of Announcement | DGAP News Service |
|
|
979211 19-Feb-2020 CET/CEST
EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.
